ArticleApplied biochemistry and biotechnology2025
Assessment of Phytochemical Profile, Antioxidant, and Anticancer Activity Against Colon Cancer-HT-29: A Potent Therapeutic Medicinal Plant (Tarenna alpestris) in Megamalai Hills, Western Ghats, India.
Article in Applied biochemistry and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Research Progress on Preparation, Transformation and Application of Protoplasts Derived from Medicinal Plants.Plants (Basel, Switzerland) · 2026Review
- GC-MS guided phytochemical profiling of Bauhinia tomentosa flowers: molecular docking against HPV-E6 and p53 in cervical cancer.Scientific reports · 2026Article
- Phytochemical composition, in vitro antioxidant and antibacterial activities of Dorstenia barnimiana Schweinf leaf extracts.BMC complementary medicine and therapies · 2026Article
- Development of bioengineered SPIONs usingOpen life sciences · 2026Article
- Antiproliferative effect of Filopaludina bengalensis fluid inducing apoptosis-necroptosis synergy with immunogenic remodelling in triple-negative breast cancer.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medicinal plants have long been recognized as a valuable source of human health due to their therapeutic potential in treating a variety of diseases. Tarenna alpestris, a plant native to the Megamalai Hills in the Western Ghats of India, has traditionally been used for numerous medicinal purposes. However, despite its extensive use in folklore, scientific validation of its therapeutic properties remains limited. This study aims to evaluate the phytochemical composition of Tarenna alpestris, assess its antioxidant properties, and explore its potential anticancer effects against HT-29 colon cancer cells. The phytochemical profile was determined using preliminary screening and gas chromatography-mass spectrometry (GC-MS). Antioxidant activity was measured through DPPH, FRAP, H₂O₂, and N₂O₂ assays. The anticancer effects were investigated using the MTT assay for cell viability, AO/EtBr staining for apoptosis detection, DAPI staining for nuclear fragmentation analysis, and flow cytometry for cell cycle analysis. The phytochemical analysis identified several bioactive compounds, including flavonoids, alkaloids, terpenoids, and phenolic acids. Sixteen phytocomponents were detected from the extract by GCMS analysis, the major compounds are 9-octadecynoic acid (21%), N-hexadecanoic acid (16%), methylene diamine, N,N'-diacetyl (15%), 1-allyl-cyclohexane-1,2-diol (11%) 2-methyl-6-methylene-octa-1,7-dien-3-ol (5%), squalene (4%), and lupeol (3%) respectively. The antioxidant assays demonstrated significant free radical scavenging activity, with IC50 values comparable to known antioxidant standards. The antioxidant enzymatic activity of Tarenna alpestris extract suggests a potent ability to neutralize reactive oxygen species and protect against oxidative damage. In vitro studies revealed that Tarenna alpestris extract significantly inhibited the proliferation of HT-29 colon cancer cells and induced apoptosis, based on concentration dependent manner. The concentration needed to inhibit 50% of cell growth, known as the IC
Indexed as
Identifiers
39946058What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.